August 2009

• 
• Share
• E-mail
• Print

PRODUCT NEWS

OTC Lightener. A non-prescription alternative to hydroquinone for the management of uneven pigmentation is now available. Lumixyl (Basis Medical) is described by the manufacturer as a non-toxic, non-irritating, synthetic peptide technology. It has been shown in studies to improve the appearance of age spots, sun spots, and uneven skin tone, they say. Lumixyl reportedly restrains tyrosinase,resulting in lightening of dark spots and discoloration associated with melasma, post-inflammatory hyperpigmentation, photodamage, and hyperpigmentation. The developer says the non-irritating, water-soluble compound has no cytotoxic effects and is not associated with allergic or irritant reactions.

Prescription Promise. A new prescription non-steroidal cream may offer an alternative to topical corticosteroids for patients with seborrheic dermatitis. Promius Pharma recently announced the launch of Promiseb Topical Cream, a non-steroidal cream that the company says has demonstrated both anti-inflammatory and antifungal properties. In a 28-day, randomized, head-to-head comparison trial, Promiseb Cream demonstrated similar statistically significant improvements as low-potency topical corticosteroid (desonide cream 0.05%) in the severity of mild to moderate seborrheic dermatitis of the face. Seventy-one percent of patients in the Promiseb Cream group who had responded by day 14 remained clear at day 28, vs. 14 percent in the desonide cream 0.05% group at day 28. Additionally, Promiseb cream was comparable to desonide cream 0.05% in reducing redness, itching, and scaling.

Re-Texture. For patients seeking an added boost in their skin care regimen, Glytone has unveiled a new at-home peel offering exfoliation and re-texturization. The Glytone Mini Peel Gel contains Glycolic Acid 10.8% Free Acid Volume and is intended for bi-weekly use. It is available exclusively through physicians with a recommended retail price of $50 for 2oz.

It's a Wash. The newest body wash from Dove promises to preserve skin proteins and lipids while restoring moisture, the company says. The new NutriumMoisture line features Directly Esterified Fatty Isethionate or DEFI tecnology foud in other Dove products coupled with technology the company says drives mositurizers into the skin and helps to preserve components of the skin 10 layers deep. They say that studies show reduced skin dryness following three weeks of product use. The line, launching this month, will include "Deep Moisture," "Sensitive Skin," and "Gentle Exfoliating" products.

FDA ACTIONS
New Filler on the Market. Coapt Systems' Hydrelle, a hyaluronic acid dermal filler formulated with lidocaine, got the FDA nod for the treatment of facial wrinkles. According to the company, Hydrelle delivers rapid results that are comparable to other hyaluronic acid fillers and provides a more comfortable injection experience. Additionaly, they say that Hydrelle is cost-effective compared to traditional fillers, since patients require approximately 50 percent of typical injection volumes.

Smothering Lice. Ulesfia (Benzyl Alcohol Lotion 5%) from Sciele is now the first and only prescription medication that kills head lice by asphyxiation without the use of potentially neurotoxic chemicals. Indicated for the topical treatment of head lice infestation in patients six months of age and older, Ulesfia is available now by prescription nationwide. It is applied to dry hair and scalp, left in place for 10 minutes, then washed away. Treatment is repeated at day seven.

Foaming at the Barrier. Recently approved Hylatopic topical emollient foam from Onset Therapeutics has just launched. The prescription foam is indicated to manage the symptoms of atopic dermatitis through a three-step approach to hydrate, protect, and restore the natural skin barrier by creating a semi-permeable physical barrier. Designed to spread over large areas, the product features Onset's proprietary alcohol-free Delevo™ foam technology, that they say absorbs easily and leaves no oily or sticky residue.

A Good Mix. FDA approved a method of mixing the dermal filler Radiesse with lidocaine, which, in clinical trials, has demonstrated an improvement in patient comfort and an increase in patient satisfaction with dermal filler procedures. BioForm Medical says it will immediately begin commercial efforts to educate physicians to use this method of mixing Radiesse with lidocaine.

Comment on this Article:

You must be logged in to leave a comment.

TOP 5 ARTICLES FROM 2009

• Therapeutics Update
• Non-steroidal, Antifungal, Anti-inflammatory Cream for Seborrheic Dermatitis

  Suitable for use as monotherapy or an as adjunct to traditional therapies, a new formulation provides more options in the management of this somewhat common condition.

  By Joseph Bikowski, MD

• Pearls for the Diagnosis and Management of Eyelid and Lip Dermatitis

  With sensitivity to diagnostic clues and initiation of appropriate therapeutic strategies, clinicians can eliminate irritant dermatitis of the lips and eyelids.

  By Matthew J. Zirwas, MD

• Manage and Prevent Isotretinoin Side Effects

  This guide will help you anticipate and prevent or minimize side effects that your patients can develop as a result of isotretinoin therapy.

  By Michael Stierstorfer, MD

• Itchy Hives and Ice Cubes: Cold Urticaria in Children

  Although rare, cold-induced urticaria is a potentially life-threatening condition that may be under-recognized in the pediatric population.

  By Jessica W. Hsu, BS and Sarah E. Hill, MD